Mineralys Prices $150M Stock Offering to Fund Royalty Repurchase

Mineralys Therapeutics, Inc. announced the pricing of an underwritten public offering of 5,660,378 shares of its common stock at $26.50 per share, anticipating approximately $150.0 million in gross proceeds. The company plans to use the net proceeds to fund a portion of the $200.0 million upfront payment for the repurchase of a royalty obligation from Tanabe Pharma Corporation. This capital raise follows an earlier announcement of a $500 million committed debt facility, highlighting significant financial activities.